{"id":747665,"date":"2023-04-13T17:58:20","date_gmt":"2023-04-13T21:58:20","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/oncternal-therapeutics-participating-in-oppenheimer-co-s-virtual-fireside-chat-discussion-of-ror1-car-t-cell-therapy-in-hematological-malignancies-and-solid-tumors\/"},"modified":"2023-04-13T17:58:20","modified_gmt":"2023-04-13T21:58:20","slug":"oncternal-therapeutics-participating-in-oppenheimer-co-s-virtual-fireside-chat-discussion-of-ror1-car-t-cell-therapy-in-hematological-malignancies-and-solid-tumors","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/oncternal-therapeutics-participating-in-oppenheimer-co-s-virtual-fireside-chat-discussion-of-ror1-car-t-cell-therapy-in-hematological-malignancies-and-solid-tumors\/","title":{"rendered":"Oncternal Therapeutics Participating in Oppenheimer &amp; Co.\u2019s Virtual Fireside Chat: Discussion of ROR1 CAR T Cell Therapy in Hematological Malignancies and Solid Tumors"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">SAN DIEGO, April  13, 2023  (GLOBE NEWSWIRE) &#8212; Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that two key industry opinion leaders and management will participate in Oppenheimer &amp; Co.\u2019s Virtual Fireside Chat: Discussion of ROR1 CAR-T Cell Therapy in Hematological Malignancies and Solid Tumors on <strong>Tuesday, April 18, 2023 at 1:30 p.m. EDT.<\/strong><\/p>\n<p>Oppenheimer &amp; Co. Senior Research Biotech Analyst, Hartaj Singh, will moderate a discussion with:<\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:3pt\">Michael Wang, M.D., Endowed Professor in the Department of Lymphoma &amp; Myeloma at MD Anderson Cancer Center<\/li>\n<li style=\"margin-top:3pt\">Angela Shen, M.D, Ph.D., Associate Professor, Medicine, Harvard Medical School Director of Cellular Immunotherapy, Cancer Center, Massachusetts General Hospital<\/li>\n<li style=\"margin-top:3pt\">James Breitmeyer, M.D, Ph.D., Oncternal\u2019s President and Chief Executive Officer<\/li>\n<\/ul>\n<p>Please contact your Oppenheimer &amp; Co. institutional salesperson to participate in the call. Links to the replay will be accessible on the Events &amp; Presentations page of the Investors section on the Company\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=CCmvgIiPIWImuwAxzlonDDjCKqLzWjwkxMpVyVk4aHbRFhep6slJ386fbf4mBbeYLFEZdtdfsQ8mwjOae2_HVlT6qCsJg3TbJDzRUGioh_E=\" rel=\"nofollow noopener\" target=\"_blank\">investor.oncternal.com<\/a>, for at least 30 days after the event.<\/p>\n<p>\n        <strong>About Oncternal Therapeutics<\/strong><br \/>\n        <br \/>Oncternal Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies for the treatment of patients with cancers that have critical unmet medical need. Oncternal pursues drug development targeting promising, yet untapped biological pathways implicated in cancer generation or progression, focusing on hematological malignancies and prostate cancer. <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Ec1BqZmV3Rc5wfdLvvwMzTpucPBA4vmkQCs6kETymvQjQOKNaJYiQ5TLfx6WhkiycnulVyOOPTmlSIJkr3t2it8kHNYMs1NEMEur9fOfaDuOrM-8ugFljeMfaQI5TWzw5_BNR1AhzUdfWxnXnwqB6-14YNiwX9MJS0r1KV2aHBetd1F9P89I_GrEjoJ_PpM8UNP1GJmsTjX7iKPTz3YhJCAjOY36ZXySX03QV6hF_8BE-eZ5_O8m7JSDrYUqF5vGoohHwuM0Fy8iRZbFrGDISdn1eesp4r9jfFdeQJwhngvJYpFa8i0nHfL6yNNY2H7iCofagGL0k8Rhyj4QPaP8ib-wVExfvS3UIOTSZV-snwESzophW6J3uhuChYZ0u6VDJvWu5VEFSs1ZrYPz8Sp6yGlTjf-NY_TJDl0pqoMsbnwX4NuiGFJ_4Cwh--eNCTmH\" rel=\"nofollow noopener\" target=\"_blank\"><u>ONCT-808<\/u><\/a> is an investigational autologous chimeric antigen receptor T (CAR T) cell therapy that targets Receptor Tyrosine Kinase-Like Orphan Receptor 1 (ROR1) using the binding domain from zilovertamab. ONCT-808 has demonstrated activity in preclinical models against multiple hematological malignancies and solid tumors and has been shown to be specific for cancer cells expressing ROR1. Oncternal has developed a robust and reproducible manufacturing process that has the potential to reduce the time patients must wait for their individual CAR T product to be produced, compared with approved CAR T products. Oncternal has initiated Study ONCT-808-101 (<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=lPVsKDM5-Vs-eF1ni9Cfcs1mM-ZdTj-2u3Bh2o_TdNvAdYgEwSojFdzHUr3cSeZ5F3YQrKw-_zPdvSTToLbu0P-tWYlff0uIvtKs9Ast5aQ=\" rel=\"nofollow noopener\" target=\"_blank\"><u>NCT05588440<\/u><\/a>) for the treatment of patients with relapsed or refractory aggressive B-cell lymphoma, including patients who have failed previous CD19 CAR T treatment. <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ocT3vEvJK2ejeFT7o-0kloosHLhNGuaPhatH7DdnxdmUAyDAGlIDz4Z6g8ib8lZuTv_CJLAzC9uriyQ_9elLOKcDFHgIJQlCoHXEpF6Dt-Bhmw6h0fmc4-f-ESoBQL65U2Vkh8uMeNBNg-46CZl-uL7cNEFYOlMoLXMHqIDFPlmkrD1SUsEHInnleTCVZxPbQ-sNGz3PMQAcQDIubT4Co0HIQurGZeWIGVuD6n5w42a5nPg3CEQtkx_5qkeQ7abpZkfnD0T_KqM5NcPAg_qslMhXxNZDoGVL2XW7p_YwE75kHBTqe7OdhQvQLP-N4JjB4mj6iIineZQuovByzM5i4EhR6o4nny58iL1uUiBbr4TyWnvgxHfUKzclBE4kLW1IxIl-r5v-iSG61t5Atybl7IQcHPeC2HDwoj05roIgVa9vm1Ttu9DsizeneN3LrhEU\" rel=\"nofollow noopener\" target=\"_blank\"><u>ONCT-534<\/u><\/a> is a dual-action androgen receptor inhibitor (DAARI) with preclinical activity in prostate cancer models against both unmutated androgen receptor (AR), and against multiple forms of AR mutation. It is a potential treatment for patients with mCRPC and unmet medical need because of resistance to androgen receptor inhibitors, including those with AR amplification, mutations in the AR ligand binding domain (LBD), or splice variants with loss of the AR LBD. Final IND-enabling studies for ONCT-534 have been completed. <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=S5xrEl5c-Lawq5Wr0DbKK612tg4R10OrlieZu5mAQv1ZrCOb7lX_1IOlN3VkcY3gRti65wupWvseNMj6ggzXjHUMxsmc8g_8ZZUk4vSP3JzjdhkwmNvkRG8oUqtmzKSV84ehG5QxDyRc8KJI5fbTkKeWNLFn54dUa0vZ_tyQ188j2eH1FMQ-l_SdVRchAOvhikIqE3XAb6ppBpbcxXb3xDdBhKDLB6iFGKNZep-4ObCl2zq1DkZWSVfFegW1LXrWM5t5Tv5AHbeXc5wVd_Bs2WpPPlodoaqLYMkITn_W2p5Pdubq6Vc3qeBJWA81ezz2DCdxHp1Az3goBh8cXOqH3BxyNo3ic95efeTmXJ4aVZ25Uqsg2UON_I8BWjqaLYhTvoMIyU09tbvs6WW2Yao0XLsRlZnmpnv4q5ZgjnkyJCuopdXhsPPnlfsG51xOJXXO7QO_eiWHyKYPeqgZR8WEtsU7QwaF3iwqeb0PDP0nOiA=\" rel=\"nofollow noopener\" target=\"_blank\"><u>Zilovertamab<\/u><\/a> is an investigational monoclonal antibody designed to inhibit the function of ROR1. Zilovertamab has been evaluated in Phase 1\/2 Study CIRM-0001 (<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Kma25FFUdKql_-j5y3trjjSY7VqrbSX1KeKEX1fF23uqCsyn1Cm4vVJQIzTlKUlLq2kuGn43eDPX8WJUjIN8UE7D6rjzY75qpTu4wuenRu0=\" rel=\"nofollow noopener\" target=\"_blank\"><u>NCT03088878<\/u><\/a>) in combination with ibrutinib for the treatment of patients with MCL, chronic lymphocytic leukemia (CLL) and marginal zone lymphoma (MZL). Zilovertamab is also being evaluated in two investigator-initiated studies: a Phase 2 clinical trial of zilovertamab in combination with venetoclax, a Bcl-2 inhibitor, in patients with R\/R CLL (<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=tQfYs_xDVRaUFeO-xMTlaO4_7oI1wBK11TYFxXvnodl9yiEm7q7qSR3_-I5HMM9JSn5IgQXsrhWPJI40Ns3x_fgpHJ5tqbq1AJvhZ1lTzwA=\" rel=\"nofollow noopener\" target=\"_blank\"><u>NCT04501939<\/u><\/a>), and a Phase 1b study of zilovertamab in combination with docetaxel in patients with metastatic castration-resistant prostate cancer (<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=HH6rlnumzf_yw8yV4G2jOcRNCxnza6zgterAmlKq3ecU62Qbf-d8fXvx8EjYShxbU9QDr14JncrcV2B3HMB-E-T6jJCoVz_xqJjhruGknhs=\" rel=\"nofollow noopener\" target=\"_blank\"><u>NCT05156905<\/u><\/a>). More information on our company and programs is available at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=D3jQ5-2gopOcVndpCUopWz6QAExvEIYh6Apjq2qajHVr6dWnVxni6miY8aJATL8ch1PY8l07Cs5kas6LdhVTLAybaWH46HgY-8yo98sBi1kIqmIXf12rtlZkqzTBTlbPR8MkdL8Hlj8Af_uOOP0MNWyfaXtsTbTBq9_9ek3v8uCukbukxcW1GDXNE_dMOQQNLLUx6--J_sATunYnN91dyBpmM_9-8nKckkc6RxPRo42JuC8YB8QZP12SoeOAB8fsuJFU0W2kUe2pJp8BhBhpscd5xA1Jw_LO_Ej3T8l4E41UAvTfi0sHRvFDmN_Ruy636kHaIHuYwKA9CQib9cfdD-breAEHl24aKH8tpC9ysJykupZxSaljO3wkHJjfEKMVqooC88Mc8wwOyRLeY8pUPYflmd1-H6x59mGK1nWw0QeWbAwoi8XTvloY9TPXxNIjj8v_FzEP-U37FIecfovSg9inr-Kzrie9hVNT6JnDR64=\" rel=\"nofollow noopener\" target=\"_blank\"><u>https:\/\/oncternal.com\/<\/u><\/a><u>.<\/u><\/p>\n<p>\n        <strong>Contact Information:<\/strong>\n      <\/p>\n<p>\n        <strong>Investors<\/strong><br \/>\n        <br \/>Richard Vincent <br \/>858-434-1113<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=-SX59YN5GF6lVonJ2jsFg_juHuJa37Of_jpcm-lyHB82p0e0Lo7SZWB-ssJFfFWJtaECoi8KtYledBcT-j1g8YyrobUU0NAPLKrc8uC7wzo=\" rel=\"nofollow noopener\" target=\"_blank\"><u>rvincent@oncternal.com<\/u><\/a><\/p>\n<p>\n        <strong>Media<\/strong><br \/>\n        <br \/>Corey Davis, Ph.D. \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 <br \/>LifeSci Advisors \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 <br \/>212-915-2577\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 <br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=WB09zjbepyJEaCDAVxT-HZu0EadHrpd6JetuO49vHE7LGP5JKPe91kZk7Nnd5lk3l_P6yngoKX9XqQCbiKpK2UWShpNylhDduB-PnXxZJ9pmO9AoWWPXLdCKA2udi8eV\" rel=\"nofollow noopener\" target=\"_blank\"><u>cdavis@lifesciadvisors.com<\/u><\/a><\/p>\n<p \/>\n      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwNzY5MSM1NTI1ODMxIzUwMDA3NDE2MQ==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/NWUyZWJmZTctOTUxYy00MGI0LTg2NWUtYmU3Y2U0YmU2OGQ5LTUwMDA3NDE2MQ==\/tiny\/Oncternal-Therapeutics.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SAN DIEGO, April 13, 2023 (GLOBE NEWSWIRE) &#8212; Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that two key industry opinion leaders and management will participate in Oppenheimer &amp; Co.\u2019s Virtual Fireside Chat: Discussion of ROR1 CAR-T Cell Therapy in Hematological Malignancies and Solid Tumors on Tuesday, April 18, 2023 at 1:30 p.m. EDT. Oppenheimer &amp; Co. Senior Research Biotech Analyst, Hartaj Singh, will moderate a discussion with: Michael Wang, M.D., Endowed Professor in the Department of Lymphoma &amp; Myeloma at MD Anderson Cancer Center Angela Shen, M.D, Ph.D., Associate Professor, Medicine, Harvard Medical School Director of Cellular Immunotherapy, Cancer Center, Massachusetts General Hospital James Breitmeyer, M.D, Ph.D., Oncternal\u2019s &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/oncternal-therapeutics-participating-in-oppenheimer-co-s-virtual-fireside-chat-discussion-of-ror1-car-t-cell-therapy-in-hematological-malignancies-and-solid-tumors\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Oncternal Therapeutics Participating in Oppenheimer &amp; Co.\u2019s Virtual Fireside Chat: Discussion of ROR1 CAR T Cell Therapy in Hematological Malignancies and Solid Tumors&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-747665","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Oncternal Therapeutics Participating in Oppenheimer &amp; Co.\u2019s Virtual Fireside Chat: Discussion of ROR1 CAR T Cell Therapy in Hematological Malignancies and Solid Tumors - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/oncternal-therapeutics-participating-in-oppenheimer-co-s-virtual-fireside-chat-discussion-of-ror1-car-t-cell-therapy-in-hematological-malignancies-and-solid-tumors\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Oncternal Therapeutics Participating in Oppenheimer &amp; Co.\u2019s Virtual Fireside Chat: Discussion of ROR1 CAR T Cell Therapy in Hematological Malignancies and Solid Tumors - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SAN DIEGO, April 13, 2023 (GLOBE NEWSWIRE) &#8212; Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that two key industry opinion leaders and management will participate in Oppenheimer &amp; Co.\u2019s Virtual Fireside Chat: Discussion of ROR1 CAR-T Cell Therapy in Hematological Malignancies and Solid Tumors on Tuesday, April 18, 2023 at 1:30 p.m. EDT. Oppenheimer &amp; Co. Senior Research Biotech Analyst, Hartaj Singh, will moderate a discussion with: Michael Wang, M.D., Endowed Professor in the Department of Lymphoma &amp; Myeloma at MD Anderson Cancer Center Angela Shen, M.D, Ph.D., Associate Professor, Medicine, Harvard Medical School Director of Cellular Immunotherapy, Cancer Center, Massachusetts General Hospital James Breitmeyer, M.D, Ph.D., Oncternal\u2019s &hellip; Continue reading &quot;Oncternal Therapeutics Participating in Oppenheimer &amp; Co.\u2019s Virtual Fireside Chat: Discussion of ROR1 CAR T Cell Therapy in Hematological Malignancies and Solid Tumors&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/oncternal-therapeutics-participating-in-oppenheimer-co-s-virtual-fireside-chat-discussion-of-ror1-car-t-cell-therapy-in-hematological-malignancies-and-solid-tumors\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-13T21:58:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwNzY5MSM1NTI1ODMxIzUwMDA3NDE2MQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncternal-therapeutics-participating-in-oppenheimer-co-s-virtual-fireside-chat-discussion-of-ror1-car-t-cell-therapy-in-hematological-malignancies-and-solid-tumors\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncternal-therapeutics-participating-in-oppenheimer-co-s-virtual-fireside-chat-discussion-of-ror1-car-t-cell-therapy-in-hematological-malignancies-and-solid-tumors\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Oncternal Therapeutics Participating in Oppenheimer &amp; Co.\u2019s Virtual Fireside Chat: Discussion of ROR1 CAR T Cell Therapy in Hematological Malignancies and Solid Tumors\",\"datePublished\":\"2023-04-13T21:58:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncternal-therapeutics-participating-in-oppenheimer-co-s-virtual-fireside-chat-discussion-of-ror1-car-t-cell-therapy-in-hematological-malignancies-and-solid-tumors\\\/\"},\"wordCount\":572,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncternal-therapeutics-participating-in-oppenheimer-co-s-virtual-fireside-chat-discussion-of-ror1-car-t-cell-therapy-in-hematological-malignancies-and-solid-tumors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgwNzY5MSM1NTI1ODMxIzUwMDA3NDE2MQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncternal-therapeutics-participating-in-oppenheimer-co-s-virtual-fireside-chat-discussion-of-ror1-car-t-cell-therapy-in-hematological-malignancies-and-solid-tumors\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncternal-therapeutics-participating-in-oppenheimer-co-s-virtual-fireside-chat-discussion-of-ror1-car-t-cell-therapy-in-hematological-malignancies-and-solid-tumors\\\/\",\"name\":\"Oncternal Therapeutics Participating in Oppenheimer &amp; Co.\u2019s Virtual Fireside Chat: Discussion of ROR1 CAR T Cell Therapy in Hematological Malignancies and Solid Tumors - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncternal-therapeutics-participating-in-oppenheimer-co-s-virtual-fireside-chat-discussion-of-ror1-car-t-cell-therapy-in-hematological-malignancies-and-solid-tumors\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncternal-therapeutics-participating-in-oppenheimer-co-s-virtual-fireside-chat-discussion-of-ror1-car-t-cell-therapy-in-hematological-malignancies-and-solid-tumors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgwNzY5MSM1NTI1ODMxIzUwMDA3NDE2MQ==\",\"datePublished\":\"2023-04-13T21:58:20+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncternal-therapeutics-participating-in-oppenheimer-co-s-virtual-fireside-chat-discussion-of-ror1-car-t-cell-therapy-in-hematological-malignancies-and-solid-tumors\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncternal-therapeutics-participating-in-oppenheimer-co-s-virtual-fireside-chat-discussion-of-ror1-car-t-cell-therapy-in-hematological-malignancies-and-solid-tumors\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncternal-therapeutics-participating-in-oppenheimer-co-s-virtual-fireside-chat-discussion-of-ror1-car-t-cell-therapy-in-hematological-malignancies-and-solid-tumors\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgwNzY5MSM1NTI1ODMxIzUwMDA3NDE2MQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgwNzY5MSM1NTI1ODMxIzUwMDA3NDE2MQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncternal-therapeutics-participating-in-oppenheimer-co-s-virtual-fireside-chat-discussion-of-ror1-car-t-cell-therapy-in-hematological-malignancies-and-solid-tumors\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Oncternal Therapeutics Participating in Oppenheimer &amp; Co.\u2019s Virtual Fireside Chat: Discussion of ROR1 CAR T Cell Therapy in Hematological Malignancies and Solid Tumors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Oncternal Therapeutics Participating in Oppenheimer &amp; Co.\u2019s Virtual Fireside Chat: Discussion of ROR1 CAR T Cell Therapy in Hematological Malignancies and Solid Tumors - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/oncternal-therapeutics-participating-in-oppenheimer-co-s-virtual-fireside-chat-discussion-of-ror1-car-t-cell-therapy-in-hematological-malignancies-and-solid-tumors\/","og_locale":"en_US","og_type":"article","og_title":"Oncternal Therapeutics Participating in Oppenheimer &amp; Co.\u2019s Virtual Fireside Chat: Discussion of ROR1 CAR T Cell Therapy in Hematological Malignancies and Solid Tumors - Market Newsdesk","og_description":"SAN DIEGO, April 13, 2023 (GLOBE NEWSWIRE) &#8212; Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that two key industry opinion leaders and management will participate in Oppenheimer &amp; Co.\u2019s Virtual Fireside Chat: Discussion of ROR1 CAR-T Cell Therapy in Hematological Malignancies and Solid Tumors on Tuesday, April 18, 2023 at 1:30 p.m. EDT. Oppenheimer &amp; Co. Senior Research Biotech Analyst, Hartaj Singh, will moderate a discussion with: Michael Wang, M.D., Endowed Professor in the Department of Lymphoma &amp; Myeloma at MD Anderson Cancer Center Angela Shen, M.D, Ph.D., Associate Professor, Medicine, Harvard Medical School Director of Cellular Immunotherapy, Cancer Center, Massachusetts General Hospital James Breitmeyer, M.D, Ph.D., Oncternal\u2019s &hellip; Continue reading \"Oncternal Therapeutics Participating in Oppenheimer &amp; Co.\u2019s Virtual Fireside Chat: Discussion of ROR1 CAR T Cell Therapy in Hematological Malignancies and Solid Tumors\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/oncternal-therapeutics-participating-in-oppenheimer-co-s-virtual-fireside-chat-discussion-of-ror1-car-t-cell-therapy-in-hematological-malignancies-and-solid-tumors\/","og_site_name":"Market Newsdesk","article_published_time":"2023-04-13T21:58:20+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwNzY5MSM1NTI1ODMxIzUwMDA3NDE2MQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncternal-therapeutics-participating-in-oppenheimer-co-s-virtual-fireside-chat-discussion-of-ror1-car-t-cell-therapy-in-hematological-malignancies-and-solid-tumors\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncternal-therapeutics-participating-in-oppenheimer-co-s-virtual-fireside-chat-discussion-of-ror1-car-t-cell-therapy-in-hematological-malignancies-and-solid-tumors\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Oncternal Therapeutics Participating in Oppenheimer &amp; Co.\u2019s Virtual Fireside Chat: Discussion of ROR1 CAR T Cell Therapy in Hematological Malignancies and Solid Tumors","datePublished":"2023-04-13T21:58:20+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncternal-therapeutics-participating-in-oppenheimer-co-s-virtual-fireside-chat-discussion-of-ror1-car-t-cell-therapy-in-hematological-malignancies-and-solid-tumors\/"},"wordCount":572,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncternal-therapeutics-participating-in-oppenheimer-co-s-virtual-fireside-chat-discussion-of-ror1-car-t-cell-therapy-in-hematological-malignancies-and-solid-tumors\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwNzY5MSM1NTI1ODMxIzUwMDA3NDE2MQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncternal-therapeutics-participating-in-oppenheimer-co-s-virtual-fireside-chat-discussion-of-ror1-car-t-cell-therapy-in-hematological-malignancies-and-solid-tumors\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/oncternal-therapeutics-participating-in-oppenheimer-co-s-virtual-fireside-chat-discussion-of-ror1-car-t-cell-therapy-in-hematological-malignancies-and-solid-tumors\/","name":"Oncternal Therapeutics Participating in Oppenheimer &amp; Co.\u2019s Virtual Fireside Chat: Discussion of ROR1 CAR T Cell Therapy in Hematological Malignancies and Solid Tumors - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncternal-therapeutics-participating-in-oppenheimer-co-s-virtual-fireside-chat-discussion-of-ror1-car-t-cell-therapy-in-hematological-malignancies-and-solid-tumors\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncternal-therapeutics-participating-in-oppenheimer-co-s-virtual-fireside-chat-discussion-of-ror1-car-t-cell-therapy-in-hematological-malignancies-and-solid-tumors\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwNzY5MSM1NTI1ODMxIzUwMDA3NDE2MQ==","datePublished":"2023-04-13T21:58:20+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncternal-therapeutics-participating-in-oppenheimer-co-s-virtual-fireside-chat-discussion-of-ror1-car-t-cell-therapy-in-hematological-malignancies-and-solid-tumors\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/oncternal-therapeutics-participating-in-oppenheimer-co-s-virtual-fireside-chat-discussion-of-ror1-car-t-cell-therapy-in-hematological-malignancies-and-solid-tumors\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncternal-therapeutics-participating-in-oppenheimer-co-s-virtual-fireside-chat-discussion-of-ror1-car-t-cell-therapy-in-hematological-malignancies-and-solid-tumors\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwNzY5MSM1NTI1ODMxIzUwMDA3NDE2MQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwNzY5MSM1NTI1ODMxIzUwMDA3NDE2MQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncternal-therapeutics-participating-in-oppenheimer-co-s-virtual-fireside-chat-discussion-of-ror1-car-t-cell-therapy-in-hematological-malignancies-and-solid-tumors\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Oncternal Therapeutics Participating in Oppenheimer &amp; Co.\u2019s Virtual Fireside Chat: Discussion of ROR1 CAR T Cell Therapy in Hematological Malignancies and Solid Tumors"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/747665","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=747665"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/747665\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=747665"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=747665"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=747665"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}